At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 93 enrolled
Drug / intervention
T2750 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
In Brief
A Phase 3 clinical trial evaluating T2750 and Vismed for Dry Eye Syndromes. Completed, enrolled 93 participants across 1 site.
Detailed Summary
Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedApr 2012
Primary CompletionMar 2013
TodayJul 2026
First PostedApr 2, 2012
Enrollment StartMar 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.3 years ago
Interventions
T2750device
1 drop in each eye 3 to 6 times daily during 84 days
Vismeddevice
1 drop in each eye 3 to 6 times daily during 84 days